Weekly Digest - October 2026

Weekly Digest - October 2026

12 October 2026: DR30206 fusion protein received China IND approval for combination therapy in HNSCC

  • Huadong Medicine’s DR30206, an antibody fusion protein has received China NMPA approval to initiate a clinical trial in combination with standard chemotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma
  • The approval enables clinical evaluation of the combination in HNSCC, building on DR30206’s ongoing phase 1/2 development across advanced solid tumors. Earlier studies have reported a favorable safety profile and preliminary antitumor activity signals
  • The program addresses the need for additional treatment options in recurrent or metastatic HNSCC, where disease progression and resistance to available therapies remain significant challenges
  • DR30206 is a triple-targeting antibody fusion protein that simultaneously targets PD-L1, VEGF and TGF-β. It is designed to restore antitumor immune activity through PD-1/PD-L1 pathway blockade, inhibit tumor angiogenesis through VEGF neutralization, and reduce immunosuppression by targeting TGF-β
  • Strategically, the new IND approval broadens DR30206’s clinical development across multiple solid tumors and combination regimens. Its triple-targeting mechanism differentiates the program from conventional checkpoint inhibitors and supports Huadong Medicine’s strategy of developing multi-targeted biologics for oncology

For full story click  here

Share this